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Background: Alcoholic cardiomyopathy (CMP) is one of the major complications of chronic excessive alcohol
consumption. The pathogenic mechanisms implicated are diverse, inducing functional and structural changes in
the myocardium. Insulin-like Growth Factor 1 (IGF-1) plays an important role in modulating the cell cycle, and helps
the differentiation and proliferation of cardiac tissue inhibiting apoptosis. Experimental studies have suggested the
role of IGF-1 in alcohol-induced cardiac damage. The aim of the present study was to determine the effect of
chronic alcohol consumption on IGF-1 myocardial expression and to compare this expression in cases of
hypertension and other cardiac diseases.
Methods: We studied heart samples from human organ donors: 10 healthy donors, 16 with hypertension, 23 with
chronic alcohol consumption and 7 with other causes of cardiac disease. IGF-1 myocardial expression was
evaluated with a specific immunohistochemistry assay using a semi-quantitative method.
Results: A significant decrease in IGF-1 myocardial expression was observed comparing all the cases included with
control donors. This decrease in IGF-1 myocardial expression was significantly lower in the group of donors with
chronic alcohol consumption compared to controls. On group evaluation according to the presence of CMP,
donors with chronic alcohol consumption without CMP presented significantly lower IGF-1 expression than
controls, whereas donors with chronic alcohol consumption with CMP showed a downward trend without
achieving significance.
Conclusions: Chronic alcohol consumption significantly reduces IGF-1 myocardial expression. This decrease
induced by alcohol is partially compensated in the presence of structural myocardial damage.
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Although there is evidence that moderate alcohol
consumption has some beneficial effects in health [1],
chronic and excessive alcohol intake can lead to the de-
velopment of dilated cardiomyopathy (CMP) and other
cardiovascular diseases [2-5]. Almost 1 in 3 alcoholic
misusers develop heart disease, whether alcoholic CMP,
cardiac hypertrophy, arrhythmias or reduced myocardial
contractility [6].
Alcoholic CMP is one of the major complications of
chronic alcoholism [5], developing in a dose-dependent* Correspondence: jfernand@clinic.ub.es
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distribution, and reproduction in any mediummanner, independently of vitamin or nutritional deficits
[7-9]. The cumulative lifetime dose of alcohol needed to
develop alcoholic CMP has been assessed as 7 kg per kg
of body weight of ethanol in men and 5 kg in women
[10]. Alcoholic CMP is characterized by progressive
structural and functional changes in the myocardium
that remain subclinical for years until the appearance of
heart failure or arrhythmia [10]. There is also a direct re-
lationship between cardiac dysfunction and skeletal my-
opathy in patients with alcoholic CMP [11].
The physiopathological mechanisms implicated in
alcohol-induced toxic damage to striated skeletal and
cardiac muscle are multifactorial and are probably
additive [12,13], being apoptosis, oxidative damage and
contractile protein disruption the most relevant [3,12].
In previous studies in chronic alcoholic donors, weCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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lar degree as that caused by hypertension. This effect
was more prominent in alcoholic donors with already
developed heart damage [14]. In another study we ob-
served that hearts from donors without alcoholic CMP
presented over-expression of L-type calcium channels, a
fact that increases Ca2+ entry into the cells and induces
myocyte damage [9].
Recently, some authors described the potential effect
that diverse myocyte growth factors such myostatin and
IGF-1 may exert in regulating the development of alcohol-
induced heart damage. Myostatin is a growth factor that,
when up-regulated, inhibits the proliferation of muscle
and cardiac myocytes, for this reason it is down-regulated
during tissue development [15]. We have reported an in-
crease in myostatin myocardium activity in subjects with
CMP either of alcoholic or non alcoholic origin [16].
Insulin-like Growth Factor 1 (IGF-1) is a simple string
of polypeptides with a structure similar to proinsulin.
IGF-1 has short-term effects on the proliferation and dif-
ferentiation of different cell types including cardiac
myocytes. Its mitogenic activity is mediated by its bind-
ing to a IGF-1 receptor found on the cell surface [17,18].
Growth hormone (GH) is linked to IGF-1 receptor by
IGF-1 promoting growth and tissue differentiation [19,20].
The direct effect of IGF-1 on cells is related to DNA syn-
thesis, cell cycle gene modulation and induction of cell
entry to the S phase. IGF-1 activation induces cell prolifer-
ation and increases protein synthesis, resulting in cell
hypertrophy and promoting tissue protection. It also has
an anti-apoptotic effect mediated by inhibition of Bax
induction, caspase activation and DNA fragmentation
[17,21,22]. Local myocardium activity of IGF-1 is most
relevant than that produced elsewhere (i.e. in the liver). In
fact, the bioavailability of exogenous administered IGF-1
is limited, because of the rapid clearance (half time < 10
min) of this peptide hormone from the circulation [23].
Some studies have evaluated the role of IGF-1 and GH
in cardiac function and induction of myocyte damage
after an ischemic heart attack. Both GH and IGF-1 have
been shown to have a therapeutic effect on heart failure
[19,20]. A study done in alcohol-fed rats demonstrated a
reduction in IGF-I mRNA content in liver and skeletal
muscle, compared with pair-fed control rats [24]. An ex-
perimental study on IGF-1 in mice showed that over-
expression of this growth hormone has a beneficial effect
on the myocardial dysfunction caused by excessive con-
sumption of alcohol [2]. No previous clinical investiga-
tions have studied the direct effect of alcohol on IGF-1
in humans.
Considering the previously noted pro-apoptotic effect
of ethanol [14] as well as the up-regulation of myocyte
myostatin, [16], and based on data from experimental
studies on myocardial IGF-1 effect, we aimed to evaluatethe potential role of IGF-1 in the development of alcohol-
induced cardiac damage. Thus, we hypothesized that
chronic alcohol consumption has an inhibitory effect on
IGF-1 expression, and may consequently worsen the re-
covery of damaged myocardial tissue. For this purpose, we
studied samples of human myocardium tissue from organ
donors. Donors were classified into different groups
according to alcohol consumption, the presence of CMP
or the existence of hypertension or other causes of myo-
cardial damage. The main objective in the present study
was to evaluate myocardium IGF-1 expression in human
organ donors and determine the effect of chronic alcohol
consumption, the presence of CMP, hypertension or other
causes of myocardial damage.
Results
We included a total of 57 hearts samples from human
donors collected at the Hospital Clínic Transplant Unit
between January 2006 to December 2008. One sample
which was not adequately cryopreserved was excluded.
Therefore, a total of 56 heart samples were finally evalu-
ated. Heart samples were divided into 4 groups as fol-
lows: (1) 10 healthy donors without evidence of alcohol
consumption, hypertension or other causes of heart dis-
ease (control group), (2) 16 non-alcoholic hypertensive
donors, (3) 23 donors with chronic alcohol consumption
and (4) 7 non-alcoholic donors with other causes of
cardiac disease. Table 1 shows the epidemiological and
clinical data of donors according to these four groups. Re-
markably there were no differences related to age and gen-
der distribution between groups. Alcoholics presented a
higher tobacco use compared to healthy non-alcoholic do-
nors. None of these subjects presented criteria of caloric
or protein malnutrition. As expected, donors with chronic
alcohol consumption, hypertension and other cardiac dis-
eases presented significant changes in echocardiography
parameters and also in morphometrical parameters of
myocardial hypertrophy compared to controls.
To evaluate the effect of CMP on IGF-1 myocardial
expression, these cases were further divided in 6 groups:
(1) 10 healthy non-alcoholic donors, (2) 8 hypertensive
non-alcoholic donors without CMP, (3) 8 hypertensive
non-alcoholic donors with CMP, (4) 11 donors with
chronic alcohol consumption without CMP, (5) 12 do-
nors with chronic alcohol consumption with CMP and
(6) 7 non-alcoholic donors with other causes of CMP (2
ischemic disease, 3 valve disease and 2 idiopathic CMP).
As expected, the cases (groups 2, 3, 4, 5 and 6)
presented a higher cardiothoracic index, lower left
ventricular ejection fraction and electrocardiogram ab-
normalities and showed a worse clinical class than
controls (group 1). The consumption of daily alcohol in-
take (38.57 ± 12.10 vs. 43.94 ± 11.66, in g/day; p=0.676)
and lifetime dose of ethanol (5.04 ± 2.54 vs. 3.50 ± 1.10
Table 1 Epidemiologic and clinical data of the different groups of heart donors
Control donors
(n=10)
Hypertensive donors
(n=16)
Alcoholic donors
(n=23)
Donors with other causes
of cardiac disease (n=7)
Age (y; mean (SD)) 52.3 (22.1) 62.1 (10.7) 54.3 (10.0) 59.1 (13.8)
Male/female ratio (n) 3:7 8:8 19:4 6:1
Daily alcohol intake (g; mean (SD)) 0 10.7 (19.4) 148.2 (54.9)*** 8.6 (22.8)
Lifetime dose of ethanol (kg ethanol/kg body
weight; mean (SD))
0 0.54 (0.2) 15.5 (8.3)*** 0.77 (0.2)
Active smokers [n (%)] 1 (10) 4 (25) 17 (74)*** 2 (29)
Time from admission to donation (h; mean (SD)) 30 (2) 30 (3) 33 (2) 30 (2)
NYHA function [n (%)]
Class I 10 (100) 11 (68) 12 (51) 4 (57)
Class II 0 4 (26) 7 (30) 2 (29)
Classes III and IV 0 1 (6) 2 ( 9) 1 (14)
Cardiothoracic index (mean (SD)) 0.47 (0.01) 0.54 (0.05)** 0.54 (0.05)** 0.58 (0.05)**
Electrocardiogram [abnormal cases; n (%)] 1 (10) 11 (69)* 10 (43)** 7 (100)*
Left ventricular ejection fraction (%; mean (SD)) 61 (3) 45 (9)** 45 (7)** 41 (7)**
End-diastolic diameter (mm; mean (SD)) 46.6 (2.2) 52.5 (5.1) ** 58.4 (6.2) ** 59.6 (6.4) **
End-systolic diameter (mm; mean (SD)) 29.7 (2.9) 38.3 (3.8) ** 43.8 (5.7) ** 45.4 (6.2) **
Left ventricular mass (g/m2; mean (SD)) 107 (6) 139 (10) ** 143 (11) ** 146 (13) **
Cell hypertrophy [n (%)] 0 (0) 11 (69) ** 17 (74) ** 7 (100) **
Nuclear hypertrophy [n (%)] 0 (0) 14 (88) ** 19 (82) ** 7 (100) **
An abnormal electrocardiogram is characterized by the presence of rhythm disturbances, conduction defects, signs of left ventricular hypertrophy, or
abnormal repolarization.
* P < 0.05 compared to the other groups.
** P < 0 .01 compared with control donors.
*** P < 0.01 compared to the other groups.
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consumption (10.43 ± 2.82 vs. 10.30 ± 2.66 in ciga-
rettes/day; p=0.892), was similar in the group of alco-
holic donors when divided according to the presence of
structural CMP.Figure 1 Insulin-like growth factor 1 (IGF-1) immunohistochemical ex
Negative control without IGF-1 antibody. (B) Positive control sample fromIGF-1 immunohistochemical myocardial expression
We first evaluated the presence of appropriate immuno-
histochemical IGF-1 myocardial expression. Thus, samples
without IGF-1 antibody were observed to be uniformly
negative only with hematoxylin staining, whilst samplespression in myocardium at 10 μm (magnification ×100). (A)
a healthy donor with IGF-1 antibody.
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IGF-1, with dark brown staining in the nucleus (Figure 1).
In a magnified image (Figure 2) we can see further staining
in nuclear expression of cardiac cells with some showing
clear IGF-1 expression and other cells with absent IGF-1
expression.
With respect to IGF-1 immunohistochemical expres-
sion, on division of the samples into healthy non-alcoholic
donors (controls) and cases (the latter including hyperten-
sion, chronic alcohol consumption and other causes of
cardiac disease), the IGF-1 expression index was 0.0439 ±
0.0127 versus 0.0219 ± 0.0026, respectively, with a signifi-
cant decrease in IGF-1 myocardial expression in cases
compared to controls (p=0.007) (Figure 3).
Then, we compared IGF-1 myocardial expression in
healthy non-alcoholic donors used as controls with hyper-
tensive donors, donors with chronic alcohol consumption
and donors with other causes of cardiac disease separately
(Table 2). Remarkably, we just found a significant decrease
in IGF-1 myocardial expression on comparing donors with
chronic alcohol consumption with controls (0.0206 ±
0.0042 vs. 0.0439 ± 0.0127, respectively, p=0.002). Hyper-
tensive donors tended to express low IGF-1 myocardial ex-
pression compared to controls, albeit without achieving
statistical significance (0.0250 ± 0.0043 vs. 0.0439 ± 0.0127,
respectively, p=0.068).
In order to assess the influence of the presence of
structural CMP in IGF-1 myocardial expression, we com-
pared IGF-1 expression index in all cases and controls di-
vided according to the presence or absence of structural
CMP (n=29 in donors without CMP donors, and n=27 in
donors with CMP). Thus, the IGF-1 myocardial expressionFigure 2 Insulin-like growth factor 1 (IGF-1)
immunohistochemical expression in myocardium at 10 μm
(magnification ×400). (1) IGF-1 positive nuclear expression.
(2) Negative nucleus without IGF-1 expression.in the two groups did not significantly differ (0.0274 ±
0.0053 in donors without CMP compared to 0.0241 ±
0.0037 in donors with CMP, p=0.749). We also evaluated
the relationship between IGF-1 myocardial activity and the
presence myocyte hypertrophy. Thus, myocyte IGF-1 activ-
ity was higher in donors without nuclear morphometric
hypertrophy than in donors with nuclear hypertrophy
(0.037 ± 0.009 vs 0.022 ± 0.0038, P= 0.020). Similarly, IGF-
1 myocyte activity in donors without cell hypertrophy was
significantly higher compared to their counterpart not af-
fected of cell hypertrophy (0.034 ± 0.006 vs 0.020 ± 0.002,
P= 0.048). IGF-1 myocardial activity was similar in alco-
holics with higher tobacco use and alcoholics with non-
tobacco use.
Finally, the IGF-1 myocardial expression of non-
alcoholic healthy controls was separately compared with
that of each group of cases according to the presence of
structural CMP. Only the group of donors with chronic
alcohol consumption non-affected of CMP showed sig-
nificantly lower IGF-1 myocardial expression compared
to non-alcoholic controls (0.0132 ± 0.0012 vs. 0.0439 ±
0.0127, respectively, p=0.000). Donors with chronic alco-
hol consumption with CMP tended to express lower IGF-
1 myocardial expression, but without achieving significant
differences compared to non-alcoholic controls (0.0264 ±
0.0074 vs. 0.0439 ± 0.0127, respectively, p=0.069). No dif-
ferences were obtained on comparing the controls with
the other groups of cases (Table 2). When we compare do-
nors with chronic alcohol consumption with CMP versus
chronic alcohol consumption without CMP no significant
differences were found (p=0.169).
Lastly, we performed a regression analysis between pa-
rameters of ethanol consumption and IGF-1 myocardial
expression, but did not find a significant correlation
between them (R2= 0.0939 for mean daily alcohol con-
sumption and R2 = 0.0759 for lifetime cumulative dose of
alcohol and IGF-1 myocardial expression, respectively).
Discussion
This study evaluates IGF-1 expression in myocardial tis-
sue in human donors with chronic alcohol consumption
in comparison to healthy donors and also with donors
with hypertension or other cardiac diseases using an im-
munohistochemical IGF-1-specific assay. We attempted
to assess the effect that chronic alcohol consumption
may cause in IGF-1 myocardial expression in compari-
son to non-alcoholic controls and other different groups
of donors and also evaluate the influence of the presence
of structural CMP.
The main result achieved is the evidence that chronic
alcohol consumption significantly reduces IGF-1 myo-
cardial expression compared to non-alcoholic healthy
controls. Otherwise, we did not observe significant dif-
ferences in IGF-1 myocardial expression in the other
Figure 3 Box-plot comparing healthy donors and cases with respect to Insulin-like growth factor 1 (IGF-1) index expression (p=0.007).
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a non-significant downward trend. Remarkably, IGF-1
myocardial expression was lower in donors with myocar-
dial hypertrophy compared to those without hyper-
trophy. This finding probably is related to a negative
counter-regulation between myocyte IGF-1 activity and
cell hypertrophy, corroborating the influence of this
factor on myocardial hypertrophy. Finally, on evaluating
the influence of the presence of structural CMP on IGF-
1 myocardial expression we did not find significant dif-
ferences between groups with structural CMP and those
without. This IGF-1 decreased myocardial expression in
alcoholic donors was clearly significant in those without
CMP thereby excluding an effect of structural CMP on a
decrease in IGF-1 myocardial expression. In fact, theTable 2 Comparison of myocardial immunohistochemmical st
Number of samples used for immunohistochemical study: n=56 IGF
Control donors (n=10)
Hypertensive donors (n=16)
Hypertensive donors without CMP (n=8)
Hypertensive donors with CMP (n=8)
Chronic alcohol consumption donors (n=23)
Chronic alcohol consumption donors without CMP (n=11)
Chronic alcohol consumption donors with CMP (n=12)
Donors with other causes of cardiac disease (n=7)
Data are expressed as IGF-1 index expression (SD).
IGF-1 Insulin-like Growth Factor.
CMP Cardiomyopathy.presence of structural CMP in donors with chronic
alcohol consumption non significantly increased IGF-1
myocardial expression with respect to donors without
structural CMP, a fact that may be compensatory of the
inflicted cardiac toxic damage. We also observed a down-
ward trend in IGF-1 myocardial expression in the other
groups of donors with hypertension and other cardiac dis-
eases, although without achieving significant differences
compared to controls.
Indeed, IGF-1 is a trophic factor with an important
role and short-term effects on the proliferation and
differentiation of different cell types including heart
myocytes, IGF-1 increases cardiac DNA and protein syn-
thesis and reduces protein degradation [17]. After myo-
cardial infarction IGF-1 improves cardiac function byudies in IGF-1 expression between the different groups
-1 myocardial expression p-value compared with control donors
0.0439 (0.0127)
0.0250 (0.0043) 0.068
0.0264 (0.0074) 0.101
0.0237 (0.0052) 0.173
0.0206 (0.0042) 0.002
0.0132 (0.0012) 0.000
0.0264 (0.0074) 0.069
0.0191 (0.0014) 0.161
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ing, a decrease in IGF-1 expression affects myocardial
function and myocyte regeneration [17,18].
The potential mechanism to explain this alcohol-
mediated decrease in IGF-1 myocardial expression may
be the decrease in protein synthesis and translation initi-
ation that alcohol induces in the myocardium [25]. This
effect causes a impairment in the availability and effect-
iveness of various anabolic hormones including IGF-1
[13] and myostatin [16]. These results are in concord-
ance to those observed in experimental studies in mice
in which alcohol-fed rats showed a reduction in the
IGF-1 mRNA content in liver and skeletal muscle com-
pared with pair-fed control rats [24]. In fact, it has been
suggested that IGF-1 expression protects the myocardium
tissue reducing apoptosis and increasing myocardial pro-
liferation [17]. For this reason, an alcohol-induced IGF-1
myocardial decrease in expression is partly compensated
in the presence of cardiac damage.
In the present series, alcohol donors consumed higher
tobacco dose than non alcoholic donors. However, In
the multivariate analysis we did not identify tobacco as a
variable influencing myocardial IGF-1 expression. In
addition, no biological effect between tobacco consump-
tion and IGF-1 activity or expression has been reported
up to now [26,27].
In the present study we did not obtain a significant
correlation between alcohol consumption parameters
and IGF-1 myocardial expression. This may be due to
the fact that ethanol consumption in the donors studied
was not high but rather slight or moderate. In addition,
it is clear that ethanol has diverse pathogenic effects on
the myocardium and the global noxious effect may be a
sum of diverse implicated mechanisms such as disturb-
ance in calcium transients, induction of apoptosis, an in-
crease in myostatin expression or induction of oxidative
damage [8,14,16].
With respect to the hypertensive donors included in
this study, they showed a downward trend of IGF-1
myocardial expression compared to healthy donors. This
is in concordance to what has been observed in previous
studies, in which low levels of IGF-1 were found to be
associated with hypertension in subjects without other
cardiovascular diseases [28].
One limitation of the present study was that it evalu-
ated IGF-1 myocardial expression in a medium-size
group of human donors, without considering other
pathogenic mechanisms that may also be potentially im-
plicated in alcohol-induced cardiac damage. The present
study does not include data in IGF signaling cascade or
complementary in vitro studies. The degree of daily and
lifetime alcohol consumption in the group of donors
with alcohol consumption was only moderate, thus the
effect of high-dose ethanol intake may not have beenconsidered in the present study. IGF-1 expression was
only limited to cardiac immunohistochemical without
IGF-1 receptor or intracellular IGF-1 signaling.
Conclusions
We observed a significant decrease in IGF-1 myocardial
expression in alcoholic donors without structural CMP
compared to controls. This effect was not observed in
donors with hypertension or other cause of cardiac
disease. Since IGF-1 promotes cardiac growth, improves
cardiac contractility, cardiac output, stroke volume, and
ejection fraction, it has been suggested that IGF-1 has
therapeutic potential [17,22]. As previously reported in
an experimental study in mice, over-expression of IGF-1
has a beneficial effect on the myocardial dysfunction
caused by excessive consumption of alcohol [2]. For this
reason, a potential therapeutic use of IGF-1 could be
suggested in patients with chronic alcohol consumption
to avoid progression to CMP.
Methods
Selection of patients and controls
In the transplant unit at the Hospital Clínic subjects
with brain death due to trauma or cerebrovascular causes
are routinely evaluated for possible transplantation. Of
these donors under the age of 70 years, hearts which were
not suitable for transplantation were consecutively sepa-
rated and classified into 4 groups: (1) control hearts from
healthy non-alcoholic people who were not eligible for im-
plantation because of a lack of matched receptor or size
inadequacy, (2) hypertensive non-alcoholic donors, (3) do-
nors with chronic alcohol consumption (≥60 g/day for
over 10 years), (4) non-alcoholic donors with other causes
of cardiac disease (ischemic, valve or idiopathic).
All patients were white Caucasians of Spanish descent,
who lived with their families in or around Barcelona and
none was indigent. Some of these subjects had been in-
cluded in previous studies on heart antioxidant status
[8], cardiac apoptosis [14] and myostatin activity [16].
All cases had been admitted to the intensive care unit
and ventilator and hemodynamic parameters had been
appropriately maintained at normal values throughout
hospitalization (PaO2 >60 mm Hg, systolic blood pres-
sure >100 mm Hg, and arterial pH within the normal
range). None of the patients required in-hospital cardio-
pulmonary resuscitation maneuvers. Because all patients
were maintained in similar conditions of glucose homeo-
stasis, we consider that insulin do not play a significant
role in the final measured myocardial IGF-1 activity.
The study protocol was approved by the Ethics Com-
mittee of the Hospital Clínic and informed consent was
requested from the families of the donors concerning
the use of myocardium tissue for this research protocol
study. The authors of this manuscript have certified that
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HEART Group [29].
Clinical and laboratory evaluation
A detailed history of ethanol intake was retrospectively
obtained by consultation with family members using a
structured questionnaire (“time-line follow-back method”)
[30], as previously reported [10,11]. Duration of ethanol
intake was calculated in each group as the total cumulated
period of alcohol consumption in years, either recent or
previous. The body mass index (BMI) was determined as
the actual body weight relative to the square of the body
height (kg ⁄m2). Patients were considered to have caloric
malnutrition if the BMI was <17 kg ⁄m2. Protein malnutri-
tion was assessed by the following parameters obtained at
hospital admission: hemoglobin, lymphocyte count, total
protein, retinol-binding protein, prealbumin, and albumin.
Cardiac studies
Past and present signs and symptoms of heart failure
were evaluated on consultation of medical records and
with family members of the donors, and the New York
Heart Association (NYHA) functional class was deter-
mined according to the Goldman activity scale [31]. Chest
X-ray with measurement of cardiothoracic index and con-
ventional electrocardiography were performed in all cases.
A cardiothoracic index greater than 0.48 was observed in
27 patients compared to none of the controls. In these do-
nors with enlarged cardiothoracic index, bidimensional
echocardiography was performed (Hewlet Packard Sonos
2500; Hewlet Packard, Andover, MA). End-diastolic and
end-systolic diameters, the shortening fraction, left ven-
tricular (LV) mass, and the ejection fraction (EF) were
measured according to the standards of the American So-
ciety of Echocardiography [32]. Cardiomyopathy (CMP)
was defined as the presence of LVEF <50% and LV en-
largement. We observed a good correlation between the
cardiothoracic index and the LV end-diastolic diameter
(r=0.68, p<0.01). The personnel performing and evaluating
these tests had no knowledge of the alcoholic history of
the patients.
Myocardium histological studies
A 3 cm distal sample of the LV apex was surgically ex-
cised avoiding damaged areas (total weight of 4 to 5
grams) at the time the donor was under cold perfusion.
The specimen was cut into fragments, and one of these
was processed for further histological analysis.
Immunohistochemistry
Myocardial samples were preserved at −80°C. Immuno-
histochemical processing required cutting of samples to
10 μM using cryotome and fixation on glass slides. The
slices were kept frozen (−80°C) until the time of use.Slices were fixed with acetone for 10 minutes and then
proceed to warming in the oven at 95°C for 30 minutes
with citrate buffer (2.94 g Tri-sodium citrate + 1000 ml
H2O + 0.5 ml Tween 20 at pH 6 with HCl 1N) and let
cool for 20 minutes at room temperature. Slices were
cleaned with PBS and blocked with H2O2 (1%) for 15
minutes and were thereafter cleaned again with PBS.
Immunohistochemical analysis for IGF-1 expression
was chosen because myocardial IGF-1 expression was
considered to be the most relevant parameter in the
physiopathology of myocardial IGF-1 effects, as previ-
ously reported in other studies [33,34]. Immunohisto-
chemical detection of IGF-1 expression was evaluated
using a commercial kit of a polyclonal rabbit antibody
(IGF-1 antibody, ab9572, Abcam, Cambridge, UK). The
antibody is a recombinant immunogen (human Insulin-
like Growth Factor-1). The antibody dilution used was 4
μg/ml in a solution of blocking serum 1.5% in PBS and
was incubated overnight at 4°C. In each sample we also
performed a negative control processed without primary
antibody. Detection was performed by the compatible
secondary antibody (rabbit ABC Staining System, sc-2018,
Santa Cruz Biotechnology Inc., Santa Cruz, CA) linked to
peroxidase. A last cleaning with H2O was performed and
slices were stained with Gill’s hematoxylin 2 for 10 mi-
nutes and cleaned with H2O for 5 minutes. Finally, slides
were prepared with an aqueous mounting agent (Aquatex,
Darmstadt, Germany).
Microscopic evaluation
Myocardial cell and nuclear hypertrophy was evaluated
by histological morphometry, as previously reported [11].
IGF-1 myocardial expression was evaluated with immuno-
histochemical methods using optical microscopy at ×200
magnification with a semiquantitative approach, counting
the percentage of positive cells with respect to total evalu-
ated myocardial cells. We measured the positive IFG-1
expression in both the nucleus and cytoplasm of the
myocytes. Six areas of each sample were evaluated, includ-
ing 200 to 600 cells per field. A minimum of 1,200 cells
per sample were counted. IGF-1 expression index was cal-
culated according to the ratio between positive-stained
myocytes divided by negative-stained myocytes. Results
from control donors were compared to those of hyperten-
sive, chronic alcohol consumers and donors with other
causes of cardiac disease. In the three last groups we also
analyzed the effect of the presence of structural CMP on
IGF-1 myocardial expression.
Statistical analysis
The data were analyzed using SPSS-PC 18.0 statistical soft-
ware (SPSS, Chicago, IL). Firstly, descriptive statistics were
calculated and tested for normality (Kolmogorov-Smirnov).
Although the groups follow a normal distribution due to
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(Mann–Whitney) to assess the presence of significant dif-
ferences between the parameters studied. A significance
level lower than 0.05 was used.
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